Replies to post #40587 on NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

Ready,

You are complete right but only that the DMC would decide to have a look, which depends on not the information arm data but "the aggregated data of the P3 trial, which are unblinded" but can certainly suggest of "exceptionally good" results.

Things like that rarely happen, but when it comes it is 100% like that of today's story about lower the blood pressure as low as 120 for the senior with high blood pressure for health benefits in a landmark trial call Sprint, which is stopped very earlier. The article appears in NY Times:

http://www.nytimes.com/2015/09/12/health/blood-pressure-study.html?hp&action=click&pgtype=Homepage&module=first-column-region®ion=top-news&WT.nav=top-news&_r=0